Science Lessons: What the Business of Biotech Taught Me about Management
Widely regarded as the most innovative, successful biotech firm ever, Amgen led its industry in revenue and sales growth in 2007. Top magazines including Fortune and Industry Week have repeatedly named it one of America's best companies to work for.
In Science Lessons, Gordon Binder—CEO and chairman during 1988-2000—describes Amgen's climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its spectacular success. The turning point? The 1989 launch of Epogen, which dramatically helped kidney dialysis patients suffering from debilitating anemia. Other landmark drugs, including Neupogen, would follow.
Through engaging anecdotes and cogent insights, Binder weaves a fascinating tale while offering his unique brand of practical management advice. Using the principals of the scientific method, he shares his recommendations for tackling pressing business challenges—such as managing creative employees, navigating the IPO process, and protecting intellectual property.
This colorful first-person account showcases the visionary science and daring business strategy that made Amgen great—offering valuable lessons for all companies.
13 pages matching filed in this book
Results 1-3 of 13
What people are saying - Write a review
We haven't found any reviews in the usual places.
The Start of a StartUp
Amgen Goes Public
11 other sections not shown
Abbott Abbott Laboratories Amgen anakinra anemia application Aranesp biotech biotech firm biotechnology blood boss called cancer cells chemotherapy cinacalcet clinical trial company's corporate decision Dennis Fenton dialysis drug effective employees epoetin alfa Epogen erythropoietin filed filgrastim Fu-Kuen gene Genentech genetically engineered Genetics Institute George Rathmann going Goldwasser Gordon hired hormone idea industry initial public offering injected interview investment investors Johnson & Johnson Kevin Sharer kidney Kirby Alton Kirin knew laboratory license Litton looked manufacturing meeting ment million months Neupogen neutropenia organization partner patent percent person Pharma pharmaceutical companies phase probably protein recombinant sales and marketing scientists sell senior share someone staff staffers success testing there's thing Thousand Oaks tion took values vice president